NCT00167986

Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

Antibiotic Intervention Trial in a Medical Intensive Care Unit to Reduce the Acquisition of Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 480 (planned)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care unit (MICU).

Conditions

• Escherichia Coli Infections
• Klebsiella Infections

Interventions

Type	Name	Description
DRUG	vancomycin-resistant enterococci and ESBL

Timeline

• Start date: 2005-01-01
• First posted: 2005-09-14
• Last updated: 2007-03-15

Locations

1 site across 1 country: South Korea